Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) Stock Competitors & Peer Comparison

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, JBCHEPHARM.BO has a market cap of 387.3B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while JBCHEPHARM.BO trades at ₹2,412.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas JBCHEPHARM.BO's P/E ratio is 50.89. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to JBCHEPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check JBCHEPHARM.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, WOCKPHARMA.NS has a market cap of 306.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while WOCKPHARMA.NS trades at ₹1,886.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas WOCKPHARMA.NS's P/E ratio is 143.88. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to WOCKPHARMA.NS's ROE of +0.09%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to WOCKPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check WOCKPHARMA.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, WOCKPHARMA.BO has a market cap of 306.2B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while WOCKPHARMA.BO trades at ₹1,885.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas WOCKPHARMA.BO's P/E ratio is 143.84. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to WOCKPHARMA.BO's ROE of +0.09%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to WOCKPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check WOCKPHARMA.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, MEDPLUS.NS has a market cap of 82.8B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while MEDPLUS.NS trades at ₹689.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas MEDPLUS.NS's P/E ratio is 37.31. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to MEDPLUS.NS's ROE of +0.11%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to MEDPLUS.NS. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check MEDPLUS.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, MEDPLUS.BO has a market cap of 82.7B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while MEDPLUS.BO trades at ₹688.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas MEDPLUS.BO's P/E ratio is 36.62. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to MEDPLUS.BO's ROE of +0.11%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to MEDPLUS.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check MEDPLUS.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SANOFI.NS has a market cap of 77.2B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SANOFI.NS trades at ₹3,352.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SANOFI.NS's P/E ratio is 22.09. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SANOFI.NS's ROE of +0.40%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SANOFI.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SANOFI.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SANOFI.BO has a market cap of 77.1B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SANOFI.BO trades at ₹3,361.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SANOFI.BO's P/E ratio is 22.06. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SANOFI.BO's ROE of +0.40%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SANOFI.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SANOFI.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SUPRIYA.NS has a market cap of 64.8B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SUPRIYA.NS trades at ₹805.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SUPRIYA.NS's P/E ratio is 30.98. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SUPRIYA.NS's ROE of +0.18%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SUPRIYA.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SUPRIYA.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SUPRIYA.BO has a market cap of 64.8B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SUPRIYA.BO trades at ₹805.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SUPRIYA.BO's P/E ratio is 32.63. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SUPRIYA.BO's ROE of +0.18%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SUPRIYA.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SUPRIYA.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, KPL.BO has a market cap of 34.8B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while KPL.BO trades at ₹3,357.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas KPL.BO's P/E ratio is 83.89. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to KPL.BO's ROE of +0.28%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to KPL.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check KPL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, HIKAL.NS has a market cap of 26.6B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while HIKAL.NS trades at ₹215.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas HIKAL.NS's P/E ratio is 15.43. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to HIKAL.NS's ROE of -0.03%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to HIKAL.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check HIKAL.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, HIKAL.BO has a market cap of 26.6B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while HIKAL.BO trades at ₹216.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas HIKAL.BO's P/E ratio is 188.09. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to HIKAL.BO's ROE of -0.03%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to HIKAL.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check HIKAL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, FREDUN.BO has a market cap of 23.7B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while FREDUN.BO trades at ₹1,435.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas FREDUN.BO's P/E ratio is 56.48. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to FREDUN.BO's ROE of +0.20%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to FREDUN.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check FREDUN.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SHUKRAPHAR.BO has a market cap of 19.3B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SHUKRAPHAR.BO trades at ₹44.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SHUKRAPHAR.BO's P/E ratio is 88.22. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SHUKRAPHAR.BO's ROE of +0.48%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SHUKRAPHAR.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SHUKRAPHAR.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ACCENTMIC.NS has a market cap of 14.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ACCENTMIC.NS trades at ₹605.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ACCENTMIC.NS's P/E ratio is 32.44. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to ACCENTMIC.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ACCENTMIC.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, REMUS.NS has a market cap of 11.3B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while REMUS.NS trades at ₹961.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas REMUS.NS's P/E ratio is 26.87. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to REMUS.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check REMUS.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ONEGLOBAL.BO has a market cap of 10.8B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ONEGLOBAL.BO trades at ₹552.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ONEGLOBAL.BO's P/E ratio is 15.54. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ONEGLOBAL.BO's ROE of +0.71%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to ONEGLOBAL.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ONEGLOBAL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, BPLPHARMA.BO has a market cap of 9.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while BPLPHARMA.BO trades at ₹1,382.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas BPLPHARMA.BO's P/E ratio is -118.70. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to BPLPHARMA.BO's ROE of -0.05%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to BPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check BPLPHARMA.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SASTASUNDR.NS trades at ₹282.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SASTASUNDR.NS's P/E ratio is 34.59. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SASTASUNDR.NS's ROE of +0.00%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to SASTASUNDR.NS. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SASTASUNDR.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, VIKRAMTH.BO has a market cap of 9B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while VIKRAMTH.BO trades at ₹285.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas VIKRAMTH.BO's P/E ratio is 35.78. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to VIKRAMTH.BO's ROE of +0.32%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to VIKRAMTH.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check VIKRAMTH.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, PRAVEG.BO has a market cap of 7B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while PRAVEG.BO trades at ₹268.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas PRAVEG.BO's P/E ratio is 37.84. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to PRAVEG.BO's ROE of -0.04%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to PRAVEG.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check PRAVEG.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SGRL.BO has a market cap of 6.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SGRL.BO trades at ₹506.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SGRL.BO's P/E ratio is 39.13. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SGRL.BO's ROE of +0.10%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SGRL.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SGRL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ALBERTDA.BO trades at ₹1,084.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ALBERTDA.BO's ROE of -0.01%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to ALBERTDA.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ALBERTDA.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, BAFNAPH.BO has a market cap of 5.7B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while BAFNAPH.BO trades at ₹247.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas BAFNAPH.BO's P/E ratio is 52.67. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to BAFNAPH.BO's ROE of +0.09%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to BAFNAPH.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check BAFNAPH.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, BAFNAPH.NS has a market cap of 5.7B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while BAFNAPH.NS trades at ₹242.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas BAFNAPH.NS's P/E ratio is 51.70. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to BAFNAPH.NS's ROE of +0.09%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to BAFNAPH.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check BAFNAPH.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, JENBURPH.BO has a market cap of 4.6B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while JENBURPH.BO trades at ₹1,034.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas JENBURPH.BO's P/E ratio is 20.05. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to JENBURPH.BO's ROE of +0.18%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to JENBURPH.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check JENBURPH.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, TRANSCHEM.BO has a market cap of 4B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while TRANSCHEM.BO trades at ₹326.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas TRANSCHEM.BO's P/E ratio is 86.53. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to TRANSCHEM.BO's ROE of +0.08%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to TRANSCHEM.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check TRANSCHEM.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, INFINIUM.NS has a market cap of 3.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while INFINIUM.NS trades at ₹227.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas INFINIUM.NS's P/E ratio is 37.77. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to INFINIUM.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check INFINIUM.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, AMBALALSA.BO has a market cap of 3.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while AMBALALSA.BO trades at ₹45.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas AMBALALSA.BO's P/E ratio is 19.52. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to AMBALALSA.BO's ROE of +0.09%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to AMBALALSA.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check AMBALALSA.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, TLL.BO has a market cap of 3.4B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while TLL.BO trades at ₹282.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas TLL.BO's P/E ratio is 17.30. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to TLL.BO's ROE of +0.23%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to TLL.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check TLL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, BDH.BO has a market cap of 3.1B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while BDH.BO trades at ₹540.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas BDH.BO's P/E ratio is 36.73. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to BDH.BO's ROE of +0.16%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to BDH.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check BDH.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, GENNEX.BO has a market cap of 3.1B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while GENNEX.BO trades at ₹12.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas GENNEX.BO's P/E ratio is 15.63. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to GENNEX.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check GENNEX.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ZENOTECH.BO trades at ₹46.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ZENOTECH.BO's P/E ratio is 149.19. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ZENOTECH.BO's ROE of -0.03%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to ZENOTECH.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ZENOTECH.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, KERALAYUR.BO has a market cap of 2.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while KERALAYUR.BO trades at ₹189.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas KERALAYUR.BO's P/E ratio is -20.70. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to KERALAYUR.BO's ROE of -2.76%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to KERALAYUR.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check KERALAYUR.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SANJIVIN.BO has a market cap of 2.4B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SANJIVIN.BO trades at ₹193.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SANJIVIN.BO's P/E ratio is 51.44. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SANJIVIN.BO's ROE of +0.17%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SANJIVIN.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SANJIVIN.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, OXYGENTAPH.BO has a market cap of 2.4B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while OXYGENTAPH.BO trades at ₹63.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas OXYGENTAPH.BO's P/E ratio is -63.71. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to OXYGENTAPH.BO's ROE of +0.39%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to OXYGENTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check OXYGENTAPH.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, CORALAB.BO has a market cap of 2.3B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while CORALAB.BO trades at ₹650.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas CORALAB.BO's P/E ratio is 17.14. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to CORALAB.BO's ROE of +0.09%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to CORALAB.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check CORALAB.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, PANCHSHEEL.BO has a market cap of 1.6B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while PANCHSHEEL.BO trades at ₹118.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas PANCHSHEEL.BO's P/E ratio is 14.44. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to PANCHSHEEL.BO's ROE of +0.07%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to PANCHSHEEL.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check PANCHSHEEL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SYSCHEM.BO has a market cap of 1.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SYSCHEM.BO trades at ₹30.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SYSCHEM.BO's P/E ratio is 510.83. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SYSCHEM.BO's ROE of +0.06%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SYSCHEM.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SYSCHEM.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, AUROLAB.BO has a market cap of 1.5B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while AUROLAB.BO trades at ₹235.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas AUROLAB.BO's P/E ratio is 39.05. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to AUROLAB.BO's ROE of +0.08%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to AUROLAB.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check AUROLAB.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, PARNAXLAB.BO has a market cap of 1.4B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while PARNAXLAB.BO trades at ₹123.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas PARNAXLAB.BO's P/E ratio is 65.26. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to PARNAXLAB.BO's ROE of +0.10%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to PARNAXLAB.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check PARNAXLAB.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, QUESTLAB.NS has a market cap of 1.4B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while QUESTLAB.NS trades at ₹85.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas QUESTLAB.NS's P/E ratio is 10.37. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to QUESTLAB.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check QUESTLAB.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SMRUTHIORG.BO has a market cap of 1.4B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SMRUTHIORG.BO trades at ₹121.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SMRUTHIORG.BO's P/E ratio is 18.82. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SMRUTHIORG.BO's ROE of +0.10%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SMRUTHIORG.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SMRUTHIORG.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, KIMIABL.BO has a market cap of 1.3B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while KIMIABL.BO trades at ₹27.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas KIMIABL.BO's P/E ratio is 31.46. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to KIMIABL.BO's ROE of +0.55%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to KIMIABL.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check KIMIABL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, LACTOSE.BO has a market cap of 1.3B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while LACTOSE.BO trades at ₹100.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas LACTOSE.BO's P/E ratio is 20.79. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to LACTOSE.BO's ROE of +0.11%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to LACTOSE.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check LACTOSE.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while PHARMAID.BO trades at ₹32.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas PHARMAID.BO's P/E ratio is -42.42. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to PHARMAID.BO's ROE of -0.09%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to PHARMAID.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check PHARMAID.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, MAKERSL.BO has a market cap of 1.1B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while MAKERSL.BO trades at ₹185.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas MAKERSL.BO's P/E ratio is -146.87. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to MAKERSL.BO's ROE of +0.04%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to MAKERSL.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check MAKERSL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while TYCHE.BO trades at ₹104.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas TYCHE.BO's P/E ratio is 10.55. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to TYCHE.BO's ROE of +0.03%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to TYCHE.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check TYCHE.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, GODAVARI.BO has a market cap of 1B. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while GODAVARI.BO trades at ₹101.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas GODAVARI.BO's P/E ratio is 23.22. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to GODAVARI.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check GODAVARI.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SOTAC.NS has a market cap of 995.1M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SOTAC.NS trades at ₹90.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SOTAC.NS's P/E ratio is 11.63. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SOTAC.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SOTAC.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, DENISCHEM.BO has a market cap of 991.6M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while DENISCHEM.BO trades at ₹71.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas DENISCHEM.BO's P/E ratio is 11.79. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to DENISCHEM.BO's ROE of +0.09%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to DENISCHEM.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check DENISCHEM.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, MERCURYLAB.BO has a market cap of 914.9M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while MERCURYLAB.BO trades at ₹762.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas MERCURYLAB.BO's P/E ratio is 25.04. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to MERCURYLAB.BO's ROE of +0.07%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to MERCURYLAB.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check MERCURYLAB.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, VAISHALI.NS has a market cap of 856.5M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while VAISHALI.NS trades at ₹7.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas VAISHALI.NS's P/E ratio is -2.96. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to VAISHALI.NS's ROE of +0.06%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to VAISHALI.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check VAISHALI.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, CONCORD.BO has a market cap of 788.6M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while CONCORD.BO trades at ₹75.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas CONCORD.BO's P/E ratio is 74.75. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to CONCORD.BO's ROE of +0.03%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to CONCORD.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check CONCORD.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ZENITHDRUG.NS has a market cap of 731.4M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ZENITHDRUG.NS trades at ₹42.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ZENITHDRUG.NS's P/E ratio is 18.54. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to ZENITHDRUG.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ZENITHDRUG.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SUNLOC.BO has a market cap of 717.8M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SUNLOC.BO trades at ₹70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SUNLOC.BO's P/E ratio is 17.90. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SUNLOC.BO's ROE of +0.05%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SUNLOC.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SUNLOC.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SOURCENTRL.BO has a market cap of 693.6M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SOURCENTRL.BO trades at ₹109.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SOURCENTRL.BO's P/E ratio is 20.41. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SOURCENTRL.BO's ROE of +0.14%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to SOURCENTRL.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SOURCENTRL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, BIBCL.BO has a market cap of 682.2M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while BIBCL.BO trades at ₹15.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas BIBCL.BO's P/E ratio is -4.46. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to BIBCL.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check BIBCL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, VILINBIO.NS has a market cap of 573.3M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while VILINBIO.NS trades at ₹41.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas VILINBIO.NS's P/E ratio is 256.88. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to VILINBIO.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check VILINBIO.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, PHRMASI.BO has a market cap of 518.8M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while PHRMASI.BO trades at ₹76.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas PHRMASI.BO's P/E ratio is -26.42. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to PHRMASI.BO's ROE of +1.35%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to PHRMASI.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check PHRMASI.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, VRL.BO has a market cap of 489.4M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while VRL.BO trades at ₹154.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas VRL.BO's P/E ratio is 8.45. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to VRL.BO's ROE of +0.15%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to VRL.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check VRL.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, PARMAX.BO has a market cap of 486M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while PARMAX.BO trades at ₹129.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas PARMAX.BO's P/E ratio is -11.68. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to PARMAX.BO's ROE of +0.96%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to PARMAX.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check PARMAX.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, VISTAPH.BO has a market cap of 396.4M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while VISTAPH.BO trades at ₹6.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas VISTAPH.BO's P/E ratio is -3.34. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to VISTAPH.BO's ROE of -0.27%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to VISTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check VISTAPH.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SHELTER.BO has a market cap of 370.1M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SHELTER.BO trades at ₹32.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SHELTER.BO's P/E ratio is 6.20. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SHELTER.BO's ROE of +0.15%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to SHELTER.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SHELTER.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SANDUPHQ.BO has a market cap of 366.2M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SANDUPHQ.BO trades at ₹37.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SANDUPHQ.BO's P/E ratio is 149.45. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SANDUPHQ.BO's ROE of +0.04%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SANDUPHQ.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SANDUPHQ.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ROOPAIND.BO has a market cap of 365.4M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ROOPAIND.BO trades at ₹46.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ROOPAIND.BO's P/E ratio is 357.31. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ROOPAIND.BO's ROE of +0.01%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to ROOPAIND.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ROOPAIND.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, DECCAN.BO has a market cap of 333.9M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while DECCAN.BO trades at ₹13.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas DECCAN.BO's P/E ratio is 13.23. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to DECCAN.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check DECCAN.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ANG.BO has a market cap of 317.8M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ANG.BO trades at ₹24.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ANG.BO's P/E ratio is -2.86. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ANG.BO's ROE of -0.22%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to ANG.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ANG.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, PANJON.BO has a market cap of 306.4M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while PANJON.BO trades at ₹17.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas PANJON.BO's P/E ratio is 446.25. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to PANJON.BO's ROE of +0.04%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to PANJON.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check PANJON.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, MEDICAPQ.BO has a market cap of 306.3M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while MEDICAPQ.BO trades at ₹24.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas MEDICAPQ.BO's P/E ratio is 36.66. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to MEDICAPQ.BO's ROE of -0.02%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to MEDICAPQ.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check MEDICAPQ.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, MEDIORG.NS has a market cap of 295.6M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while MEDIORG.NS trades at ₹24.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas MEDIORG.NS's P/E ratio is -7.13. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to MEDIORG.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check MEDIORG.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, GUJTERC.BO has a market cap of 293.1M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while GUJTERC.BO trades at ₹37.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas GUJTERC.BO's P/E ratio is 41.48. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to GUJTERC.BO's ROE of +0.26%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to GUJTERC.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check GUJTERC.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, WELCURE.BO has a market cap of 271.9M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while WELCURE.BO trades at ₹0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas WELCURE.BO's P/E ratio is -10.93. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to WELCURE.BO's ROE of -0.34%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to WELCURE.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check WELCURE.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while TRIMURTHI.BO trades at ₹26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to TRIMURTHI.BO's ROE of +0.02%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to TRIMURTHI.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check TRIMURTHI.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ISHITADR.BO has a market cap of 228.9M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ISHITADR.BO trades at ₹76.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ISHITADR.BO's P/E ratio is 192.02. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ISHITADR.BO's ROE of +0.06%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to ISHITADR.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ISHITADR.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while CHEMOPH.BO trades at ₹130.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to CHEMOPH.BO's ROE of -0.92%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to CHEMOPH.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check CHEMOPH.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, COLINZ.BO has a market cap of 195.7M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while COLINZ.BO trades at ₹74.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas COLINZ.BO's P/E ratio is 184.93. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to COLINZ.BO's ROE of +0.28%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to COLINZ.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check COLINZ.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, BACPHAR.BO has a market cap of 176.5M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while BACPHAR.BO trades at ₹12.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas BACPHAR.BO's P/E ratio is 41.20. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to BACPHAR.BO's ROE of +0.03%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to BACPHAR.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check BACPHAR.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SUNREST.NS has a market cap of 175.9M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SUNREST.NS trades at ₹41.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SUNREST.NS's P/E ratio is 8.78. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SUNREST.NS. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SUNREST.NS's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ZENLABS.BO has a market cap of 169.3M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ZENLABS.BO trades at ₹26.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ZENLABS.BO's P/E ratio is -8.75. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ZENLABS.BO's ROE of -0.19%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to ZENLABS.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ZENLABS.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, NORRIS.BO has a market cap of 156M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while NORRIS.BO trades at ₹15.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to NORRIS.BO's ROE of +0.02%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to NORRIS.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check NORRIS.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, SHAMROIN.BO has a market cap of 140.9M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while SHAMROIN.BO trades at ₹25.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas SHAMROIN.BO's P/E ratio is -282.42. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to SHAMROIN.BO's ROE of -0.98%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to SHAMROIN.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check SHAMROIN.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, EMMESSA.BO has a market cap of 119.5M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while EMMESSA.BO trades at ₹23.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas EMMESSA.BO's P/E ratio is 79.73. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to EMMESSA.BO's ROE of +0.05%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to EMMESSA.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check EMMESSA.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, KOBO.BO has a market cap of 115.8M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while KOBO.BO trades at ₹4.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas KOBO.BO's P/E ratio is -9.40. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to KOBO.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check KOBO.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, BERLDRG.BO has a market cap of 115.6M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while BERLDRG.BO trades at ₹22.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas BERLDRG.BO's P/E ratio is 37.13. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to BERLDRG.BO's ROE of +0.07%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to BERLDRG.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check BERLDRG.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, TRINITYLEA.BO has a market cap of 76M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while TRINITYLEA.BO trades at ₹9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas TRINITYLEA.BO's P/E ratio is -48.00. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to TRINITYLEA.BO's ROE of -0.06%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to TRINITYLEA.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check TRINITYLEA.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while GANGAPHARM.BO trades at ₹12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to GANGAPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check GANGAPHARM.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, VIVANZA.BO has a market cap of 70M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while VIVANZA.BO trades at ₹1.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas VIVANZA.BO's P/E ratio is -180.41. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to VIVANZA.BO's ROE of +0.10%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to VIVANZA.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check VIVANZA.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, HINDBIO.BO has a market cap of 68.8M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while HINDBIO.BO trades at ₹6.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas HINDBIO.BO's P/E ratio is 45.52. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to HINDBIO.BO's ROE of -0.24%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to HINDBIO.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check HINDBIO.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, ADLINE.BO has a market cap of 65.4M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while ADLINE.BO trades at ₹11.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to ADLINE.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check ADLINE.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while TIAANC.BO trades at ₹6.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas TIAANC.BO's P/E ratio is -48.31. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to TIAANC.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check TIAANC.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, DECIPHER.BO has a market cap of 58.1M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while DECIPHER.BO trades at ₹5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas DECIPHER.BO's P/E ratio is -0.72. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to DECIPHER.BO's ROE of -0.09%. Regarding short-term risk, SUDARSHAN.BO is less volatile compared to DECIPHER.BO. This indicates lower risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check DECIPHER.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, FABINO.BO has a market cap of 42.7M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while FABINO.BO trades at ₹20.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas FABINO.BO's P/E ratio is -7.64. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to FABINO.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check FABINO.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, TMTIND-B1.BO has a market cap of 41.9M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while TMTIND-B1.BO trades at ₹8.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas TMTIND-B1.BO's P/E ratio is -46.94. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to TMTIND-B1.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check TMTIND-B1.BO's competition here

Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUDARSHAN.BO stands at 9.5B. In comparison, PATIDAR.BO has a market cap of 27.5M. Regarding current trading prices, SUDARSHAN.BO is priced at ₹38.17 on the BSE, while PATIDAR.BO trades at ₹5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUDARSHAN.BO currently has a P/E ratio of 39.35, whereas PATIDAR.BO's P/E ratio is -11.63. In terms of profitability, SUDARSHAN.BO's ROE is +0.18%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, SUDARSHAN.BO is more volatile compared to PATIDAR.BO. This indicates higher risk in terms of short-term price fluctuations for SUDARSHAN.BO.Check PATIDAR.BO's competition here